Fernando Fernandez Net Worth

The estimated Net Worth of Fernando L Fernandez is at least $38.8 ezer dollars as of 13 January 2018. Mr. Fernandez owns over 14,277 units of BioCardia stock worth over $38,833 and over the last 8 years he sold BCDA stock worth over $0. In addition, he makes $0 as Independent Director at BioCardia.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Fernandez BCDA stock SEC Form 4 insiders trading

Fernando has made over 1 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 14,277 units of BCDA stock worth $38,833 on 13 January 2018.

The largest trade he's ever made was exercising 14,277 units of BioCardia stock on 13 January 2018 worth over $38,833. On average, Fernando trades about 4,759 units every 0 days since 2017. As of 13 January 2018 he still owns at least 14,277 units of BioCardia stock.

You can see the complete history of Mr. Fernandez stock trades at the bottom of the page.

Fernando Fernandez biography

Fernando L. Fernandez CPA serves as Independent Director of the Company. He was appointed to our board of directors in October 2016. Mr. Fernandez has served as the Vice President of Finance and Chief Financial Officer of United Data Technologies, an information technology company, since November 2016. Mr. Fernandez served as the Market Vice President and Chief Financial Officer of the Care Delivery segment of Humana, Inc., a health and well-being company, from December 2012 to October 2016. From June 2004 to December 2012, Mr. Fernandez served as the Senior Vice President of Finance and Chief Financial Officer of Continucare Corporation, a medical care service company. He currently serves as a director for South Florida Business Forum since January 2018. Mr. Fernandez spent his early career in public accounting and finance functions at other companies, including Whitman Education Group, Inc., Frost-Nevada LP, and PriceWaterhouseCoopers LLP. Mr. Fernandez holds a Bachelor of Business Administration, Accounting from the University of Miami, and is a CPA.

How old is Fernando Fernandez?

Fernando Fernandez is 58, he's been the Independent Director of BioCardia since 2016. There are 8 older and 5 younger executives at BioCardia. The oldest executive at BioCardia Inc. is Simon Stertzer, 83, who is the Independent Chairman of the Board.

What's Fernando Fernandez's mailing address?

Fernando's mailing address filed with the SEC is 125 Shoreway Rd, San Carlos, CA 94070, USA.

Insiders trading at BioCardia

Over the last 8 years, insiders at BioCardia have traded over $2,555,815 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer és Richard M Krasno. On average, BioCardia executives and independent directors trade stock every 48 days with the average trade being worth of $1,321,186. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 19 January 2024, trading 129,802 units of BCDA stock currently worth $55,815.

What does BioCardia do?

we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.

Complete history of Mr. Fernandez stock trades at BioCardia

BioCardia executives and stock owners

BioCardia executives and other stock owners filed with the SEC include:

• Peter Altman,
  President, Chief Executive Officer, Director
• Henricus Duckers,
  Chief Medical Officer
• David McClung,
  Chief Financial Officer
• Dr. Peter A. Altman,
  CEO, Pres & Director
• David McClung,
  Chief Financial Officer
• Phil Pesta,
  Vice President - Operations
• Richard Krasno,
  Independent Director
• Simon Stertzer,
  Independent Chairman of the Board
• Richard Pfenniger,
  Independent Director
• Jay Moyes,
  Independent Director
• Fernando Fernandez,
  Independent Director
• Andrew Blank,
  Independent Director
• Jim Allen,
  Independent Director
• Dr. Sujith Shetty,
  Chief Medical Officer and VP of Clinical & Regulatory
• Edward M. Gillis,
  Sr. VP of Devices
• Dr. Ian McNiece Ph.D.,
  Chief Scientific Officer
• Allan R Tessler,
  Director
• Richard T Allen,
  Vice President of Quality
• Thomas Quertermous,
  Director
• Eric Duckers,
  Chief Medical Officer
• Phillip Md Et Al Frost Gamm...,